EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma
This study is testing an experimental medicine called LP-184 for people with advanced or spreading bladder cancer (also known as urothelial cancer). When this cancer spreads to other parts of the body, standard treatments may stop working, so new options are urgently needed. The trial has two main stages. In the first stage, doctors are testing different amounts of LP-184 to find the safest and most effective dose with the fewest side effects. In the second stage, researchers will test this chosen dose in a larger group to see if it shrinks tumours and helps patients live longer without their cancer getting worse. Taking part is voluntary and open to adults aged 18 and over who have advanced urothelial cancer. The findings will help doctors understand whether LP-184 could become a helpful new treatment in the future.
At a glance
What is this study about?
Urothelial cancer is the most common type of bladder cancer. It starts in the cells that line the inside of the bladder and other parts of the urinary system. When the cancer is advanced or metastatic, it means it has grown into nearby tissues or spread to other parts of the body. In these stages, cancer can become difficult to control with existing treatments, which is why researchers are looking for new medicines.
This study tests a new drug called LP-184. LP-184 is designed to attack cancer cells by damaging their genetic material (DNA), making it harder for the tumour to grow and survive. Because it is a new medicine, doctors need to study how it behaves in the human body and ensure it is safe.
The trial is split into two phases. The first phase focuses on safety. Doctors will carefully monitor small groups of patients to find the highest dose that can be given safely without causing intolerable side effects. Once that dose is found, the second phase will measure how well the drug actually works at shrinking tumours and keeping the cancer stable over time.
By taking part, patients help doctors learn whether LP-184 could offer a valuable new treatment option for people facing advanced urinary tract cancers in the years ahead.
Key takeaways
- Tests a new medicine, LP-184, for advanced or spreading bladder cancer.
- Aims to find the safest dose and discover how well the drug shrinks tumours.
- Open to adults aged 18 and over who meet specific medical criteria.
- Requires regular hospital visits for treatment, blood tests, and health scans.
- Participation is completely voluntary and you can leave at any time.
Who may be eligible?
This trial is designed for adults aged 18 or older who have been diagnosed with advanced or metastatic urothelial cancer. This means the cancer has spread beyond the main tumour site and cannot be cured by surgery alone.
Because this is an early-stage study testing a new drug, patients will need to meet certain general health requirements. Usually, this means being well enough to carry out everyday activities, having reasonably healthy kidney and liver function, and not having other serious medical conditions that could make the treatment unsafe.
Your cancer specialist will review your full medical history, previous treatments, and recent scan results to confirm whether this study is suitable and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with advanced or metastatic urothelial (bladder) cancer.
- I am well enough to look after myself and manage light daily activities.
- My cancer has spread or standard treatments are no longer working well.
- I am willing to attend regular hospital appointments for check-ups and scans.
What does participation involve?
If you take part in this study, you will receive the experimental medicine LP-184 under close medical supervision. Before starting, you will have baseline health checks, which typically include blood tests, heart checks, and imaging scans (such as CT or MRI scans) to measure your cancer.
During treatment, you will need to make regular visits to the hospital or clinic. The medical team will give you the medication, ask about any symptoms or side effects, and carry out routine blood tests. You will have periodic scans to check whether the tumour is shrinking, staying the same, or growing.
Your participation will continue for as long as the treatment is helping you and side effects remain manageable. After you finish taking the study medicine, the team will keep in touch with you for regular follow-up visits or phone calls to check on your health and recovery.
Potential risks and benefits
Locations (1)
- —UnverifiedDenmark
Common questions
What is LP-184?
LP-184 is an experimental cancer drug designed to target and damage the DNA inside cancer cells, stopping them from multiplying.
Do I have to pay to take part in this study?
No. The study drug and all trial-related tests are provided free of charge, and some trials also help cover travel expenses.
Can I stop taking part if I change my mind?
Yes. You have the right to withdraw from the trial at any point, and your standard cancer care will continue as normal.
Will this drug cure my bladder cancer?
Because this cancer is advanced, a cure is unlikely. The goal is to control the cancer, shrink tumours, and help you live longer with a good quality of life.
How often will I need to visit the hospital?
Visits are usually quite frequent at the start so doctors can check your safety, but the exact schedule will be explained by the study team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.